Peptide Atlas · Peptide

Liraglutide

Liraglutide is a glucagon-like peptide-1 analogue given by once-daily subcutaneous injection.

established

provisional
PubChem 16134956
2 citations
0 discussions
0 followers
Arg34-Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1(7-37)
NN2211
Saxenda
Victoza

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

established — replicated in humans, or settled by a regulator

every claim resolves to its source

All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

- established
  Claim: SCALE: 56-week randomized trial of liraglutide 3.0 mg in weight management standing
- resolved
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP, SCALE Obesity and Prediabetes NN8022-1839 Study Group
pmid 26132939
- established
  Claim: LEADER cardiovascular outcomes trial standing
- resolved
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB, LEADER Steering Committee, LEADER Trial Investigators
pmid 27295427

A claim's standing is its latest row in an append-only history; a tombstone names the later evidence and the reason. The Graveyard and the Resurrection Yard.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.